Lupin Ltd Q4 FY2026 Concall Summary

Key Takeaways

• Record US sales, margin reset ahead: US business hit an all-time high, powered by Tolvaptan exclusivity and Mirabegron, but FY27 EBITDA margin guidance of ~25% (down from 29%) bakes in looming competition on both products.
• India script is working: Core prescription business grew 14.5% YoY (1.3x IPM) in Q4, with diabetes up 20.9%, and the chronic share target is now 70% over five years.
• The FY28 bridge is already visible: Management pointed to Pegfilgrastim, Ranibizumab, Dulera, and a 505(b)(2) Apixaban as material FY28 launches, a concrete offset to the Tolvaptan/Mirabegron cliff.
• Complex pipeline is the margin thesis: 50+ US launches in three years, 10 first-to-files, 4 biosimilars, and a doubling of complex product share are meant to structurally lift the portfolio away from pure commoditized generics.
• What to watch next quarter: The pace of Tolvaptan competition post-September patent expiry, the ramp of Pegfilgrastim from Q2/Q3, and any update on the elusive Ellipta and Symbicort/Advair filing timelines.

US Business: The Peak and the Cliff

• What drove the record: Tolvaptan as the only generic on the market, a full-year benefit from Mirabegron, generic Risperdal Consta with CGT exclusivity, and the first product from the Nanomi platform all layered on top of base business volume growth that more than offset low-single-digit price erosion.
• The competition clock is ticking: Tolvaptan's patent expires in September this year, and management has already factored that timeline into its plans. A third Mirabegron player has settled with Astellas but has not yet entered only because of product supply, not legal barriers.
• Risperdal Consta supply can't meet demand: The product has done well enough that Lupin, manufacturing as a CMO, has struggled to ramp up, while Teva's supplier also had issues, leaving a real gap in the marketplace.
• Albuterol inhaler market: GSK's green-propellant Ventolin launch is expected around Q3 of this financial year, but Lupin does not expect an adverse impact and is working on its own green-propellant MDIs.
• FY27 US revenue outlook: Management expects to sustain a billion-dollar-plus US business, but with high-single-digit or low-double-digit erosion compared to the current year as exclusivities roll off.

Vinita Gupta: "There's a real gap in the marketplace which is a nice problem to have and we're trying to see how we can best meet the incremental demand."

Margin Walk and FY27 Reset

• Gross margin improved 410 bps YoY to 73.3%: The jump came from better product mix, higher India profitability as in-licensed product share dropped from 12% to 6%, increased volume, and cost efficiencies.
• EBITDA margin dipped QoQ: The sequential decline from Q3 FY26 was driven by slightly higher manpower cost, a payment to Astellas on the Mirabegron settlement booked in manufacturing other expenses, and a foreign exchange component.
• FY27 guidance embeds the cliff: The ~25% EBITDA margin target for FY27, down from 29% in FY26, explicitly factors in competition arriving for both Mirabegron and Tolvaptan, plus an increase in R&D spend to around 8% of sales.
• Mirabegron settlement mechanics: The prepaid component hit Q4 numbers, while the ongoing per-unit cost will be partly variable (in operating expense) and partly amortized over time, with the additional per-unit cost already factored into gross margin going forward.
• Other operating income declined 21% YoY: The drop came primarily from lower export benefits under the PLI scheme during the quarter, though management expects a roughly maintainable quarterly PLI run rate into next year.

India: Outperformance with a Chronic Tilt

• Core prescription growth of 14.5% YoY in Q4 ran at 1.3x the IPM, with all key therapies outperforming market growth. Full-year prescription growth of 10.6% beat IPM's 9.9%, led by strong volume growth of 6.4% versus IPM's 2.6%.
• Diabetes segment surged 20.9% YoY in Q4 (1.4x category), while the full-year diabetes growth of 9.4% lagged the category's 12.2% because of loss of exclusivity on certain in-licensed products.
• Chronic share rose to 66% from 64% and the stated target is 70% in the next five years, supported by a ~12,000-strong sales force and a pipeline of 80+ new product launches over coming years.
• Semaglutide launch met expectations: Launched under Semanext for diabetes/endocrinology and Livarise for GI/gynaecology, it ranked second or third among branded generics in the segment within a month, with a substantial primary sales increase in the second month. The oral tablet version is planned for later this financial year.
• Lower tender sales in the GIB business partially offset the strong prescription performance.

Pipeline: The FY28 Bridge Takes Shape

• The FY28 story is already being built: Management pointed to the full-year impact of Pegfilgrastim and Ranibizumab (launching later in FY27), plus Dulera and a 505(b)(2) Apixaban new dosage form both expected in FY28, as a concrete set of material launches that offset the Tolvaptan/Mirabegron erosion.
• Pegfilgrastim ramp starts Q2/Q3 FY27 and is expected to be a material contributor to the fiscal year. The On-Body product variant is far along, with a filing planned this fiscal year and a launch targeted for FY28 or FY29.
• Biosimilars are the next respiratory: Management views the biosimilar opportunity over the next five years as very similar to the respiratory build-out, with a focus on products where Lupin can be in the first wave or among a limited number of competitors. The pipeline spans Pegfilgrastim, Ranibizumab, Aflibercept, and Etanercept (filing this fiscal year).
• Respiratory filings accelerate: Eight to nine product filings are planned for the US in FY27 alone, and a Respimat device filing is targeted for the current fiscal year.
• Dalbavancin 505(b)(2) is expected to launch in FY27, and the broader 505(b)(2) pipeline should start producing launches in the next two years.
• Ellipta and Symbicort/Advair remain open questions: Management acknowledged Ellipta (Breo and Trelegy) is still challenging and declined to provide timelines, while Symbicort and Advair HFA filing timelines were deferred to the next quarter or so.

Vinita Gupta: "In FY28, we see potentially the full year impact of Pegfilgrastim as well as Ranibizumab that we expect to launch later in FY27. That should be a material opportunity for us in FY28. We are in the final stages with Dulera at this point, just responding to the last query from the FDA and would expect that product to be in the market in FY28 plus we have a material 505(b)(2) Apixaban new dosage form that we filed to the agency."

International Markets and Specialty Build-Out

• Brazil turned around, growing 113% YoY in local currency in Q4, driven by successful commercialization of Dapagliflozin. Empagliflozin launches are planned in Brazil and South Africa this year, and Semaglutide is targeted for South Africa and Brazil this year with Canada to follow.
• VISUfarma acquisition adds Italy and Spain to the existing UK, Germany, and France footprint, with integration starting Q1 FY27. The thesis is to leverage the ophthalmology presence to cross-sell respiratory products, biosimilars, and NaMuscla, while the ophthalmology pipeline itself is expected to keep growing double digits. Management expects the asset to comfortably cross USD 100 million in revenue in two to three years.
• Capital allocation stays disciplined: Management remains focused on specialty assets in ophthalmology, pulmonology, and rare neurology for developed markets, plus India-complementary assets in existing or targeted therapy areas, but will wait for the right opportunity to deploy capital effectively.
• Long-acting injectable platform has multiple products in development, with conversations ongoing for both innovative product transactions and partner interest in co-developing long-acting versions of existing molecules.

Vinita Gupta: "Multiple areas of synergies that our team is working upon and we remain confident that this is going to be a material step in enhancing our business in Europe as well as on the specialty front."

Regulatory and Operational Updates

• Goa facility received EIR and VAI status from the USFDA during the quarter, a positive compliance milestone. Remediation at Pithampur Unit 2 remains on track.
• Employee cost increased on regular annual increments, business growth, India field force expansion, and forex translation. Manufacturing expenses rose on higher volumes and license fee payments tied to settlement agreements.
• Effective tax rate for FY27 is expected at 25%-26%, up from current levels due to the phasing out of incentives on some domestic facilities.
• First-time inclusion in the Dow Jones Best-in-Class Indices and Emerging Markets Index, plus Great Place to Work certification across 13 countries covering all global operations.

Guidance & Commitments

Key Metrics